RLT
Radioligand therapy prostate-specific membrane antigen
Advertisement
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer.
The final segment of this roundtable series discusses radiopharmaceuticals and PARP inhibitors.
Part 2 of the Radioligands session from Uromigos Live 2024 features a discussion on the SPLASH results from ESMO 2024.
The first part of five segments from the Uromigos Live 2024 session on radioligands.
The challenges of patient management and access to care are explored in the sixth part of our RLT roundtable discussion.
The fifth segment of the RLT roundtable explores recent clinical trials, including the VISION study.
The fourth part of this roundtable delves into the VISION and PSMAfore studies and their implications.
The third part of this roundtable explores imaging interpretation and toxicity management.
An expert panel discusses the evolving landscape of radioligand therapy for prostate cancer.
In the final segment of this series, Drs. Morris, Garmezy, and Chen discuss the use of novel radiopharmaceuticals.
In the fourth part of this series, the panelists discuss barriers to the use of radium-223 and other radioligands.
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
The Radioligands panel at Uromigos Live & Unplugged 2024 explored the role of RLT in prostate cancer treatment.
The roundtable of experts discuss the realities of the SPLASH trial's hazard ratio and overall survival results.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.